The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 07, 2007

Filed:

Nov. 10, 1998
Applicants:

Alessandro Sette, La Jolla, CA (US);

John Sidney, San Diego, CA (US);

Scott Southwood, Santee, CA (US);

Esteban Celis, Rochester, MN (US);

Inventors:

Alessandro Sette, La Jolla, CA (US);

John Sidney, San Diego, CA (US);

Scott Southwood, Santee, CA (US);

Esteban Celis, Rochester, MN (US);

Assignee:

IDM Pharma, Inc., Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2006.01); A61K 38/10 (2006.01); A61K 39/00 (2006.01); C07K 4/12 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus,(MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.


Find Patent Forward Citations

Loading…